Proteios Technology, Inc.
Proteios is developing 1) recombinant protein purification kits and will soon be extending the technology for the purification of biopharmaceuticals during manufacturing, 2) a multivariate cell separation technology for cell enrichment during cell therapy research and a cGMP-compliant instrument for cell therapy manufacturing of autologous CAR-T cell therapies and allogeneic NK cell therapies, and 3) a POC device for the detection of the SARS-Cov-2 virus.
Proteios' vision is to apply our technology to help lower the cost of healthcare, including: diagnostics, small-molecule drugs, biopharmaceuticals, cell therapies, and gene therapies.
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
Organization Mailing Address
580 Wilderness Peak Drive NW
Issaquah, WA 98027
cGMP instrument for multivariate cell separation during cell therapy manufacturing
Cell therapies have emerged as highly promising treatments for cancers and diseases resulting from viral infection. We are designing a cGMP instrument for multivariate cell separation during cell therapy manufacturing, with an initial focus on T cells for autologous CAR-T cell therapies and Natural Killer cells for allogeneic viral and cancer therapies. Our technology avoids the use of antibodies and magnetics beads, and allows for cell separations based on multiple factors in a single step.
Currently available technologies for cell isolation use a multi-step process. This process is time-consuming, usually requires centrifugation, and may cause cell stress and cellular damage that results in lower cell yield and viability. There is also a clear lack of alternatives for GMP-grade reagents to immunomagnetically isolate cells - both in a clinical and pharmaceutical setting.
Our approach for multivariate cell isolation uses biologically-safe reagents in a single-step process that supports multiple cell release strategies. It will allow for direct isolation of T cell and Natural Killer (NK) cells from blood with up to a 75% reduction in cell isolation time. This will make therapeutic cell isolation less strenuous, faster, more affordable, and more efficient than available antibody-based cell isolation technology. The proven ability of aptamers to isolate cells directly from blood will be combined with Proteios' strategies to efficiently synthesize aptamers, selectively capture cells on silica substrates, and selectively release target cells through orthogonal elution strategies.
We are developing an aptamer-based cell isolation platform for isolating hematopoietic progenitor cells directly from a variety of sources - such as placenta perfusate and umbilical cord blood - to initiate the cell manufacturing process by ex vivo differentiation. Our product uses an aptamer-peptide chimera in which the aptamer binds to a cell surface molecule of interest and the peptide binds to silica - which allows cells to be reversibly captured on silica. Proteios Chimera technology has three main advantages over current antibody-based cell isolation platforms: 1) aptamers can be manufactured faster than monoclonal antibodies and at a much lower cost, 2) Proteios Chimeras have a much longer shelf life than antibodies, and 3) synthesis of GMP-grade aptamers is much faster and cheaper than the production of monoclonal antibodies.
Cell therapies are a multibillion-dollar industry that is growing rapidly. In addition to their promise for combating viral infection, they are also of high interest as cancer immunotherapies - which highlights the broad need for technologies that can efficiently isolate and differentiate NK cells as well as T cells. Proteios is specifically designing a cGMP clinical instrument for cell separation without the limitations of other instruments which were designed for research and later adapted for clinical use.
Category of Innovation
Life Sciences - Life science solutions are those solutions that are delivered as a drug or device that typically require federal approval
Intended End User
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
Current immunomagnetic cell isolation technologies are expensive, lack many GMP-grade reagents, employ antibody reagents with a short shelf life - resulting in inflexibility during planning, can take up to 10 hours to complete cell separation, and can only isolate cells based on selection of one cell surface antigen factor at a time. The latter results in back-to-back cell separations to be performed to isolate on two factors (e.g., CD4 & CD8 or CD3 & CD56) with an accompany 2x increase in cost and 2x increase in time.
Idea/solution to the problem, if applicable
Proteios' multivariate cell separation technology allows for the simultaneous selection of target cells based on multiple factors, resulting in a 75% reduction in cell separation time and 50% reduction in cost of reagents. The Proteios Chimera reagent is composed of a small synthetic polypeptide and synthetic DNA aptamer, and exhibits a long shelf life and is easily produced under GMP conditions.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
Proteios Technology has received letters of support from:
Jeanette Boudreau, Ph.D., Dalhousie University, Canada
Christian Chabannon, M.D., Ph.D., Centre d'Investigations Cliniques en Biothérapies, France
Keith Jerome, M.D., Ph.D., University of Washington & Fred Hutchinson Cancer Research Center
Antonio Moreira, Ph.D., University of Maryland
Monica Thakar, M.D., Fred Hutchinson Cancer Research Center & Seattle Children's Hospital
Brian Till, M.D., Fred Hutchinson Cancer Research Center
List of Funding Sources (if applicable)
National Institutes of Health (NIH)
National Science Foundation (NSF)
University of Washington CoMotion